Serotransferrin Early Marker for Coronary Artery Disease
Analysis based on 8 articles · First reported Sep 09, 2026 · Last updated Sep 10, 2026
This is a scientific research finding with no immediate commercial product or regulatory decision, so its direct market impact is minimal. Over the longer term, it could support demand for diagnostic tests and cardiovascular therapeutics, modestly benefiting diagnostics and life-sciences companies.
Researchers at the India — Institute of Genomics and Integrative Biology, part of the India — Council of Scientific and Industrial Research in New Delhi, published a study in Acta Cardiologica showing that lower levels of serotransferrin, the blood protein that transports iron, are an early indicator of coronary artery disease (CAD). The analysis of blood serum proteins found that serotransferrin was downregulated in CAD patients compared to healthy individuals, and that it was inversely correlated with the cardiac marker troponin I. The study involved 50 CAD patients and 40 healthy people. According to corresponding author Sagarika Biswas, serotransferrin may serve as an early diagnostic marker, potentially identifying CAD earlier than routine clinical diagnosis, and could be a therapeutic target pending further molecular and clinical investigation. The team noted that longitudinal studies would be required to estimate how many years in advance serotransferrin could help identify CAD. The findings highlight the role of iron deficiency and inflammatory stress in CAD progression.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard